VivoSeq
Infectious Disease

Empyema

8

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Empyema is an early-stage landscape with 8 programs across 2 companies. The most active players are Roche, Milestone Pharmaceuticals Inc.. 3 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

80/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 3M

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

8 of 12 classified programs — the dominant modality here.

33%ALL OTHERSProtein / enzyme433%

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 13 pipeline programs.

Analysis

Trial Status

8

clinical trials

Completed4 · 50%
Not yet recruiting1 · 13%
Withdrawn1 · 13%
Recruiting1 · 13%
Unknown status1 · 13%

Clinical Trials

Trial Activity

8 trials

Evaluation of Efficacy and Safety Parameters of Different Antibiotics Regimens for Management of Empyema
Recruiting·FFayoum University·N/A·NCT06787885·90 enrolled
Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema
Not yet recruiting·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT07095361·270 enrolled
Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Completed·TThe Hospital for Sick Children·Phase 3·NCT01717742·97 enrolled
Urokinase Versus Primary Video-Assisted Thorascopic Surgery for Empyema
Completed·IInstitute of Child Health·Phase 1·NCT00144950·60 enrolled
Urokinase Versus Video-assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood
Completed·SSpanish Society of Pediatric Surgery·Phase 3·NCT00798278·200 enrolled
Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Empyema
Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT01246453·204 enrolled
Empyema Treated With tPA & DNAse
Withdrawn·—·Phase 3·NCT01862458
Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion
Unknown status·OO'Brien, Jeana D., MD, FACP, FCCP·N/A·NCT00103766·75 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)